Abbott Laboratories $ABT Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in Abbott Laboratories (NYSE:ABT) by 1.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,646,770 shares of the healthcare product maker’s stock after selling 23,024 shares during the period. Abbott Laboratories comprises about 1.8% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 16th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Abbott Laboratories were worth $206,324,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ABT. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $31,000. Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories during the 3rd quarter valued at about $33,000. Finally, Copia Wealth Management acquired a new position in shares of Abbott Laboratories in the third quarter valued at about $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on ABT shares. Piper Sandler dropped their target price on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Barclays dropped their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday. Evercore decreased their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Oppenheimer cut their price target on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.43.

Insiders Place Their Bets

In other news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares in the company, valued at $4,458,267.34. This represents a 0.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by insiders.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS trimmed its price target to $135 but kept a “buy” rating, signaling continued analyst confidence despite a lower valuation baseline. UBS Cuts Price Target
• Positive Sentiment: Coverage and analyst commentary highlight Abbott’s attractive dividend (near 3%) and “buy the dip” narratives that can support demand from income and value investors. Dividend Yield Story
• Positive Sentiment: Long‑term industry tailwinds for connected and remote patient‑monitoring devices (IoT medical devices) bolster Abbott’s devices segment outlook, a structural growth argument for investors with multi‑year horizons. IoT Medical Devices Market Report
• Neutral Sentiment: Search and options‑market activity indicate heightened investor attention and potential for near‑term volatility, but these signals are ambiguous about direction. Monitor put/call flows and volume for clues. Investor Interest Note
• Neutral Sentiment: Coverage noting that ABT has become “oversold” can increase the likelihood of a technical bounce, but oversold readings alone don’t guarantee a sustained recovery. Oversold Coverage
• Negative Sentiment: Multiple firms cut price targets or lowered expectations this week: Argus trimmed its PT to $125 and issued a pessimistic forecast, Barclays reduced expectations, Leerink cut its PT to $106 and put a “market perform” on the stock, and Daiwa downgraded ABT to “neutral” with a $92 target — collectively reducing analyst‑implied upside and pressuring sentiment. Argus Forecast Barclays Lowers Expectations Argus via MarketScreener Leerink PT Cut Daiwa Downgrade

Abbott Laboratories Stock Down 1.0%

ABT stock opened at $91.78 on Thursday. Abbott Laboratories has a one year low of $91.59 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm’s fifty day moving average is $106.77 and its 200 day moving average is $117.81. The firm has a market cap of $159.85 billion, a PE ratio of 25.71, a P/E/G ratio of 1.55 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the firm posted $1.09 earnings per share. The company’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.